
|Videos|October 18, 2016
Dr. Somlo on Novel Agents in Multiple Myeloma
Author(s)George Somlo, MD
George Somlo, MD, medical oncologist, City of Hope, discusses some of the novel agents being evaluated for the treatment of patients with multiple myeloma.
Advertisement
George Somlo, MD, medical oncologist, City of Hope, discusses some of the novel agents being evaluated for the treatment of patients with multiple myeloma.
Several new agents have been approved by the FDA in the past year, and oncologists are currently learning how to best utilize them, especially in combination with one another, explains Somlo.
The overall goal, says Somlo, is to both improve the toxicity profile of some of the older agents in this space, as well as bring the novel agents into the frontline setting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5


































